Stathmins and dys-regulated Golgi proteins should therefore be evaluated as new potential biomarkers for diagnosis, prognosis or therapy response in ALS, SMA and related motor neuron disorders. Here, SMN1 is linked to amyotrophic lateral sclerosis.